Saturday 17 October 2026
Export CNSY’s income statement to Excel — free account
Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.70
0.18
−9.57%
Follow CNSY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.89 | 7.61 | 5.13 | 7.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.67) | (6.34) | (4.26) | (4.23) | |
P/B ratio |
14.45 | 9.93 | 2.22 | 5.52 | |
Price to Tangible BV |
16.96 | 12.06 | 2.35 | 6.25 | |
EV/Sales |
12.08 | 6.80 | 3.07 | 7.67 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.04) | (1.71) | (0.76) | (1.45) | |
EV/FCF |
(3.90) | (1.66) | (0.71) | (1.34) | |
Quick Ratio |
1.22 | 0.74 | 2.07 | 0.48 | |
Current Ratio |
1.29 | 1.23 | 2.27 | 1.37 | |
Net Debt/EBITDA |
3.77 | 1.43 | 2.06 | 0.27 | |
Debt/Assets |
0.00% | 4.59% | 3.35% | 0.00% | |
Debt/Equity |
0.00 | 0.19 | 0.06 | 0.00 | |
Asset Turnover |
0.41 | 0.45 | 0.32 | 0.34 | |
Operating CF/Net income |
0.58 | 3.57 | 0.90 | 0.79 | |
Capex/Depreciation |
(0.44) | (0.21) | (8.52) | (3.64) | |
Interest Coverage |
— | — | (418.76) | (1,811.40) | |
Research and Development Expense of Revenue |
174.37% | 215.14% | 278.70% | 1,037.71% | |
Selling, General and Administrative Expense of Revenue |
246.46% | 304.90% | 513.81% | 1,265.94% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.03 | 0.05 | |
Share Based Compensation of Revenue |
37.72% | 52.16% | 99.42% | 201.95% | |
Graham Net Nets |
0.05 | 0.07 | 0.38 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(250.00%) | (237.25%) | (38.75%) | (76.89%) | |
Free Cash Flow Yield |
(22.31%) | (53.84%) | (83.79%) | (79.94%) | |
Revenue per Share |
0.33 | 0.44 | 0.15 | 0.06 | |
Operating CF per Share |
(0.59) | (2.01) | (0.94) | (1.03) | |
Capex per Share |
(0.01) | (0.01) | (0.12) | (0.07) | |
Free Cash Flow per Share |
(0.60) | (2.02) | (1.06) | (1.11) | |
Cash per Share |
3.86 | 2.81 | 2.27 | 0.34 | |
Shareholders Equity per Share |
1.18 | 1.28 | 1.80 | 0.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.18 | 1.28 | 1.80 | 0.79 | |
Free Cash Flow |
(2.58) | (6.29) | (7.06) | (7.63) | |
Working Capital |
3.97 | 2.86 | 10.07 | 3.20 | |
Capital Expenditures |
(0.03) | (0.03) | (0.82) | (0.50) | |
Net Current Asset Value |
3.97 | 2.84 | 10.07 | 3.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.80 | 1.21 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.52 | 0.72 | 1.17 | |
Average Payables |
9.77 | 8.60 | 7.69 | 6.95 | |
Average Inventory |
— | 2.23 | — | 3.16 | |
Average Assets |
12.82 | 11.48 | 15.99 | 12.19 | |
Average Common Equity |
(0.06) | (2.48) | (5.84) | 4.25 |
Columns are period end dates